KDMN - Week In Review: Sanofi Acquires Kadmon For $1.9 Billion
- France's Sanofi will acquire Kadmon Holdings of New York City in a $1.9 billion deal.
- Frontage Shanghai, a division of US-China CRO Frontage Holdings, acquired a 70% stake in Wuhan Heyan Biomedical Technology, a discovery CRO.
- Sinovac Biotech reported that a third dose of its inactivated SARS-CoV-2 vaccine improved the protection of CoronaVac by 60%, including protection from the Delta variant.
- JW Therapeutics, a Shanghai CAR-T company, was approved to launch its anti-CD-19 CAR-T to treat large B-cell lymphoma in China.
For further details see:
Week In Review: Sanofi Acquires Kadmon For $1.9 Billion